The present invention provides a novel method for measuring cholesterol efflux capacity. The present invention provides a method for measuring the cholesterol efflux capacity of HDL, the method including: a step for preparing magnetic beads obtained by converting cholesterol to a solid phase; a step for bringing the magnetic beads obtained by converting cholesterol to a solid phase into contact with an HDL-containing sample to be measured in a solution; and a step for separating the magnetic beads from the solution and measuring the amount of cholesterol in the solution after separating the magnetic beads.

The system disclosed comprises an apparatus and a method for the detection and quantification of targeted molecules in vivo. The apparatus comprises an implantable biosensor and an AC magnetic detection device. The implantable biosensor includes functionalized nanoparticles functionalized with one or more moieties that bind to a molecular target of interest. The nanoparticles are retained in a biocompatible container which allows the molecular target of interest to enter the biosensor, for example through a semipermeable port. The biosensor can be implanted minimally-invasively into humans or animals. Upon exposure of the nanoparticles to the molecular target, a change in Neel relaxation time can be externally detected and correlated to the target analytes concentration. The change in relaxation time is detected through magnetic AC spectrometric measurements at a frequency specifically tuned to the nanoparticle type of interest Additionally, a method is provided for quantifying one or several biosensors within one specimen.

A multiplex hand-held diagnostic biosensor, using two inflammatory salivary biomarkers, Human Neutrophil Elastase (HNE) and Cathepsin-G, was constructed made to potentially detect Periodontitis at an early stage is described. The use of magnetic nanoparticle biosensor method used as a device was based on the measurement of proteolytic activity using specific proteases probes. The magnetic nanoparticle biosensor device is capable of specific and quantitative detection of HNE and Cathepsin-G in solution and in spiked saliva samples with a lower detection limit of 1 pg/mL and 100 fg/mL for HNE and Cathepsin-G, respectively.

The system disclosed comprises an apparatus and a method for the detection and quantification of targeted molecules in vivo. The apparatus comprises an implantable biosensor and an AC magnetic detection device. The implantable biosensor includes functionalized nanoparticles functionalized with one or more moieties that bind to a molecular target of interest. The nanoparticles are retained in a biocompatible container which allows the molecular target of interest to enter the biosensor, for example through a semipermeable port. The biosensor can be implanted minimally-invasively into humans or animals. Upon exposure of the nanoparticles to the molecular target, a change in Neel relaxation time can be externally detected and correlated to the target analytes concentration. The change in relaxation time is detected through magnetic AC spectrometric measurements at a frequency specifically tuned to the nanoparticle type of interest Additionally, a method is provided for quantifying one or several biosensors within one specimen.